Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
Korean Circulation Journal
; : 395-405, 2018.
Article
in En
| WPRIM
| ID: wpr-738711
Responsible library:
WPRO
ABSTRACT
BACKGROUND AND OBJECTIVES: To compare cardiovascular disease (CVD) risk associated with 5 different dipeptidyl peptidase-4 inhibitors (DPP-4is) in people with type 2 diabetes. METHODS: We identified 534,327 people who were newly prescribed sitagliptin (n=167,157), vildagliptin (n=67,412), saxagliptin (n=29,479), linagliptin (n=220,672), or gemigliptin (n=49,607) between January 2013 and June 2015 using the claims database of the Korean National Health Insurance System. A Cox proportional hazards model was used to estimate hazard ratios (HRs) for major CVD events (myocardial infarction, stroke, or death) among users of different DPP-4is. The model was adjusted for sex, age, duration of DPP-4i use, use of other glucose-lowering drugs, use of antiplatelet agents, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, microvascular complications of diabetes, Charlson comorbidity index, and the calendar index year as potential confounders. RESULTS: Compared to sitagliptin users, the fully adjusted HRs for CVD events were 0.97 (95% confidence interval [CI], 0.94–1.01; p=0.163) for vildagliptin, 0.76 (95% CI, 0.71–0.81; p < 0.001) for saxagliptin, 0.95 (95% CI, 0.92–0.98; p < 0.001) for linagliptin, and 0.84 (95% CI, 0.80–0.88; p < 0.001) for gemigliptin. CONCLUSIONS: Compared to sitagliptin therapy, saxagliptin, linagliptin, and gemigliptin therapies were all associated with a lower risk of cardiovascular events.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Atrial Fibrillation
/
Platelet Aggregation Inhibitors
/
Cardiovascular Diseases
/
Comorbidity
/
Proportional Hazards Models
/
Stroke
/
Diabetes Mellitus, Type 2
/
Renal Insufficiency, Chronic
/
Dyslipidemias
/
Dipeptidyl-Peptidase IV Inhibitors
Type of study:
Etiology_studies
Country/Region as subject:
Asia
Language:
En
Journal:
Korean Circulation Journal
Year:
2018
Type:
Article